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miR-330-5p Targets Tyrosinase and Induces
Depigmentation
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TO THE EDITOR
There is increasing evidence that micro-
RNAs (miRNAs), small noncoding RNAs,
are involved in regulating melanogen-
esis. Various proteins, including TYR,
DCT, MELANA, and TYRP1, whose
mRNAs are potentially targeted by miR-
NAs orchestrate this process. miRNAs
regulate gene expression: in general,
they inhibit protein synthesis either by
repressing translation or by destabilizing/
degrading mRNAs by imperfect base
pairing to the ‘‘seed match’’ region in
the 50UTR, CDS, or 30UTR of the mRNAAccepted article preview online 26 May 2014; published online 26 June 2014
Abbreviations: MITF, microphthalmia-associated transcription factor; mRNA, microRNA; NHEM, normal
human epidermal melanocyte
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(Fabian et al., 2010). To date, 1,872
precursor miRNAs have been identified
in humans, giving rise to 2,578 mature
miRNAs (mirbase release 20). Melano-
genesis, stimulated by UVR, includes
synthesis of melanin, transport of mela-
nosomes, and transfer to surround-
ing keratinocytes. UVR downregulates
miR-145 in immortalized murine
melanocytes. Overexpression of miR-
145 seems to target myosin-5a and
interferes with melanosome transport
(Dynoodt et al., 2013). Microtubule-
based transport of melanosomes
appears to be negatively regulated by
hsa-miR-203 targeting KIF5B in mela-
noma cells and melanocytes (Noguchi
et al., 2014). Moreover, hsa-miR-125b
targets TYR and DCT, thereby affecting
melanin levels in a pigmented human
melanoma cell line and in darkly
pigmented melanocytes in the absence
of external stimuli (Kim et al., 2014). Wu
et al. (2008) claimed that anti-tyrosinase
miRNA expression system, which is
based on Pol-II-directed intronic mmu-
miR-434-5p overexpression, mediates
skin whitening in vitro and in vivo.
Injection of miR-675-3p mimics into
the skin of C57BL/6 J mice reduces mela-
nogenesis in vivo, mainly by targeting
microphthalmia-associated transcription
factor (MITF). Interestingly, miR-675 was
detected in media from keratinocyte cul-
tures, probably released from exosomes
(Kim et al., 2013). These observations
identify miRNAs as promising tools for
treatment of pigmentation disorders as
reviewed elsewhere (Yaar, 2013). How-
ever, some pigmentation genes are more
suitable targets than others for miRNA-
based strategies. For example, MITF-M
controls the expression of various genes
involved in melanogenesis, and its
expression is essential to melanocytes
(Goding, 2000; Levy et al., 2006).
Abolishing MITF-M expression leads to
an irreversible loss of melanocytes
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Figure 1. Depigmenting effects of miR-330-5 and miR-137 in MNT-1 cells. (a) Highly pigmented human melanoma cells (MNT-1) were treated with miRNA
mimics for 12 days. (b) Melanin levels after 12 days of treatment were quantified by spectrometry. (c) mRNA expression levels of pigmentation genes were assessed
by quantitative real-time reverse-transcriptase–PCR and are reported relative to the values for control mimic (miR-Ctrl)–treated MNT-1 cells. (d) Western blot
analysis. (e) Morphological changes were observed after treatment of MNT-1 cells with miR-137 mimics. Scale bar¼ 50mm (see Supplementary Information online
for additional information). a.u., arbitrary units; MITF, microphthalmia-associated transcription factor.
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(Steingrimsson et al., 2004) and hence
should be avoided.
We decided to identify miRNAs that
may act on pigmentation levels without
affecting the survival/proliferation of
melanocytes (Supplementary Figure S1
online). As a miRNA target, we chose
tyrosinase (TYR): it is the key and rate-
limiting enzyme for production of mel-
anin by hydroxylation of a monophenol
and conversion of an o-diphenol to the
corresponding o-quinone, a precursor of
melanin. Impaired tyrosinase production
leads to type I oculocutaneous albinism,
a complete or partial absence of pig-
ment in the skin, hair, and eyes, under-
lining the importance of TYR in the
pigmentation process. We used in silico
prediction (mirDIP) to identify candidate
miRNAs targeting TYR but not MITF
in humans. The four best miRNAs,
candidates for TYR, based on their
standardized score were miR-450b-5p,
miR-1208, miR-326, and miR-330-5p
(Supplementary Table S1 online). How-
ever, miR-450-5p, miR-1208, and miR-
326 were also predicted to target MITF
and were therefore excluded (Supple-
mentary Figure S2 online). By contrast,
miR-330-5p was an attractive candidate,
predicted to target TYR and also
MLANA (with less confidence) but not
MITF. It has been already shown that
miR-330-5p could affect E2F1 and SP1
in prostate cancer cells (Lee et al., 2009;
Mao et al., 2013). In melanoma cells,
E2F1 and SP1 are not modified, as
shown by quantitative real-time reverse-
transcriptase–PCR (Supplementary
Figure S3 online). We tested whether
miR-330-5p did indeed target TYR and
act on melanin levels: we overexpressed
miR-330-5p using mimics in highly
pigmented human melanoma cells
(MNT-1) and normal melanocytes for a
period of 12 days. As controls, we used
classic depigmenting agent Kojic acid
(Deo et al., 2013), small interfering
RNA against TYR, and miR-137/miR-7
mimics. Prediction score for miR-7
acting on MITF is low, whereas miR-
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Figure 2. miR-330-5p efficiently targets tyrosinase. (a) Pigmentation of MNT-1 cells decreased proportionally with increasing concentrations of miR-330-5p
mimics (5–100 nM). (b) Melanin was quantified by spectrometry. (c) The abundance of tyrosinase mRNA is inversely proportional to the concentration of
miR-330-5p mimics. (d) The tyrosinase protein concentration is inversely proportional to the concentration of miR-330-5p mimics. (e) Schematic representation of
the miR-330-5p binding site in the 30UTR of tyrosinase (TYR). (f) Luciferase reporter activity assays showing that miR-330-5p acts on the TYR 30UTR. Values
reported are means, and error bars represent the standard deviation (NS, not significant; **Po0.01 Mann–Whitney test) (see Supplementary Information online for
additional information). a.u., arbitrary units; MUT, mutant; UTR, untranslated region; WT, wild type.
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137 scored the highest (Supplementary
Table S1 online).
Melanin levels of MNT-1 cells were
significantly reduced after treatment
with miR-330-5p and miR-137 mimics
(Figure 1a and b). Overexpression of
miR-330-5p resulted in significant
reduction of tyrosinase mRNA and pro-
tein levels, as predicted (Figure 1c
and d), whereas MITF, TYRP1, DCT,
and MLANA expression levels remained
unaltered. Lack of effect of miR-330-5p
on MLANA was not surprising as the
standardized score was low. TYR
expression in normal human epidermal
melanocytes (NHEMs; Supplementary
Figure S4 online) and in two (501Mel
and T1) independent melanoma cell
lines (Supplementary Figure S5 online)
was similarly affected by miR-330-5p.
As expected, overexpression of miR-7
did not detectably affect pigmentation
or the expression of pigmentation genes
(Figure 1). As predicted, miR-137 over-
expression efficiently reduced MITF
mRNA and protein levels and therefore
pigmentation, consistent with published
data showing that MITF is a major target
of miR-137 in melanoma cells (Bemis
et al., 2008). Transgenic mice over-
expressing miR-137 develop a range of
coat color changes from dark black to
light colors, mainly due to reduced
MITF levels (Bemis et al., 2008; Dong
et al., 2012). However, miR-137 over-
expression seemed to affect survival/
morphology of MNT-1 cells and
NHEMs (Figure 1 and Supplementary
Figure S4 online), as previously reported
(Luo et al., 2013). In our conditions,
miR-125b acted on cell survival and
level of pigmentation in either MNT-1
cells or NHEM (data not shown). We
found that the effects of miR-330-5p on
TYR mRNA/protein abundance and on
overall pigmentation were dose depen-
dent (Figure 2 a–d). The amount of
endogenous miR-330-5p in culture is
very low in all tested melanoma cell
lines and in NHEM. In this respect, the
potential use of miR-330-5p is limited to
the treatment of hyperpigmentation dis-
orders. Mechanistically, miR-330-5p is
predicted to bind to positions 68–75 of
the TYR 30UTR (seed match region;
Figure 2e). To test this, we inserted this
region into a luciferase reporter vector:
miR-330-5p overexpression significantly
reduced luciferase activity (Figure 2f and
Supplementary Figure S6 online). Muta-
tions in the seed match region rescued
the luciferase activity, suggesting that the
predicted binding region is valid
(Figure 2f and Supplementary Figure S6
online). Mimic control treatment has no
effect (Supplementary Figure S6 online).
In a nonstressful environment, the pre-
sence of miR-330-5p mimic for 12 days
does not markedly affect the prolifera-
tion/survival of cells in vitro.
In summary, we show that miR-330-
5p is a potent negative regulator of
TYR, but not of MITF, in pigmented
melanoma cells and normal melano-
cytes, and that sustained overexpression
of miR-330-5p induces depigmentation
without affecting cell morphology,
proliferation, or survival. These proper-
ties qualify miR-330-5p as a strong can-
didate for the development of treatments
for hyperpigmentation-related disorders.
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